ABVC BIOPHARMA, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.42 USD | -10.69% |
|
+43.42% | +22.41% |
Financials (USD)
| Sales 2022 | 0.97 | Sales 2023 | 0.15 | Capitalization | 8.95M |
|---|---|---|---|---|---|
| Net income 2022 | -16M | Net income 2023 | -10M | EV / Sales 2022 | 24,208,439 x |
| Net Debt 2022 | 3.25M | Net Debt 2023 | 2.31M | EV / Sales 2023 | 73,880,417 x |
| P/E ratio 2022 |
-1.2
x | P/E ratio 2023 |
-0.48
x | Employees | 18 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 73.03% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -10.69% | ||
| 1 week | +43.42% | ||
| Current month | +8.40% | ||
| 1 month | +10.94% | ||
| 3 months | +9.23% | ||
| 6 months | +10.94% | ||
| Current year | +22.41% |
1 week
0.94
1.73
1 month
0.941.73
Current year
0.942.45
1 year
0.679.60
3 years
0.67299.50
5 years
0.67299.50
10 years
0.061 432.67
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | - | 23-06-22 | |
Leeds Chow
DFI | Director of Finance/CFO | 35 | 21-02-28 |
Eugene Jiang
CHM | Chairman | 38 | 15-06-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Yue Min Chung
BRD | Director/Board Member | 59 | 22-07-09 |
Shu Ling Chiang
BRD | Director/Board Member | 68 | - |
Eugene Jiang
CHM | Chairman | 38 | 15-06-30 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 1.42 | -10.69% | 2,056,011 |
| 24-04-25 | 1.59 | +7.43% | 5,357,784 |
| 24-04-24 | 1.48 | +9.63% | 6,738,031 |
| 24-04-23 | 1.35 | +29.81% | 8,641,601 |
| 24-04-22 | 1.04 | +5.04% | 311,506 |
Delayed Quote Nasdaq, April 26, 2024 at 04:00 pm EDT
More quotes
ABVC BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on development products and technologies to combat various diseases. The Company develops its pipeline by tracking medical discoveries or medical device technologies in research institutions in the Asia-Pacific region. It has a pipeline of six drugs and one medical device under development. Its pipeline includes ABV-1504, ABV-1505, ABV-1601, ABV-1701, ABV-1519, and ABV-1703. ABV-1504 is a botanical reuptake inhibitor that targets norepinephrine to treat major depressive disorder (MDD). It is developing ABV-1505 for treating attention deficit hyperactivity disorder (ADHD). It has developed ABV-1601 for treating depression in cancer patients. ABV-1701 is a vitreous substitute for vitrectomy. Its ABV-1519 is used for the treatment of non-small cell lung cancer. ABV-1703 is a drug for advanced, inoperable, or metastatic pancreatic cancer. The Company develops drugs and medical devices derived from plants.
Calendar
2024-05-12
- Q1 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
1.42
Average target price
-
| 1st Jan change | Capi. | |
|---|---|---|
| +22.41% | 14.96M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- ABVC Stock
